You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 7, 2024

STRATTERA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Strattera patents expire, and when can generic versions of Strattera launch?

Strattera is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Strattera

A generic version of STRATTERA was approved as atomoxetine hydrochloride by ZYDUS PHARMS USA INC on September 16th, 2010.

  Try a Trial

Drug patent expirations by year for STRATTERA
Drug Prices for STRATTERA

See drug prices for STRATTERA

Drug Sales Revenue Trends for STRATTERA

See drug sales revenues for STRATTERA

Recent Clinical Trials for STRATTERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brown UniversityPhase 2
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
Takeda Development Center Americas, Inc.Phase 4

See all STRATTERA clinical trials

Pharmacology for STRATTERA
Paragraph IV (Patent) Challenges for STRATTERA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
STRATTERA Capsules atomoxetine hydrochloride 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg 021411 10 2007-05-29

US Patents and Regulatory Information for STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-008 Feb 14, 2005 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-002 Nov 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-003 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-006 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for STRATTERA

See the table below for patents covering STRATTERA around the world.

Country Patent Number Title Estimated Expiration
Finland 119354 ⤷  Try a Trial
Turkey 9700627 ⤷  Try a Trial
European Patent Office 0721777 Utilisation de tomoxetine pour le traitement de l'hyperactivité induite par les troubles d'attention (Use of tomoxetine for the treatment of attention deficit/hyperactivity disorder) ⤷  Try a Trial
Czech Republic 292226 Léčivo pro léčení poruchy nedostatku pozornosti/hyperaktivity (Medicament for the treatment of attention deficit/hyperactivity disorder) ⤷  Try a Trial
China 1168095 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for STRATTERA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0721777 C00721777/01 Switzerland ⤷  Try a Trial PRODUCT NAME: ATOMOXETIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58245 08.04.2009
0721777 PA2006006,C0721777 Lithuania ⤷  Try a Trial PRODUCT NAME: ATOMOXETINUM HYDROCHLORICUM; NAT. REGISTRATION NO/DATE: LT/1/06/0431/001-LT/01/06/0431/024 20060621; FIRST REGISTRATION: PL 00006/0374-PL 00006/0379 20040527
0721777 CA 2006 00030 Denmark ⤷  Try a Trial PRODUCT NAME: ATOMOXETIN, EVENTUELT I FORM AF ET SALT DERAF, SASOM HYDROCHLORIDET
0721777 SPC012/2006 Ireland ⤷  Try a Trial SPC012/2006: 20061020, EXPIRES: 20190526
0721777 300180 Netherlands ⤷  Try a Trial 300180, 20160109, EXPIRES: 20190526
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.